Targeted Medical Pharma (TRGM) stock price, revenue, and financials

Targeted Medical Pharma market cap is $559.9 k, and annual revenue was $5.26 m in FY 2015

$559.9 K

TRGM Mkt cap, 09-Jul-2020

$5.3 M

Targeted Medical Pharma Revenue FY, 2015
Targeted Medical Pharma Gross profit (FY, 2015)3.2 M
Targeted Medical Pharma Gross profit margin (FY, 2015), %60.2%
Targeted Medical Pharma Net income (FY, 2015)-3.1 M
Targeted Medical Pharma EBIT (FY, 2015)-2 M
Targeted Medical Pharma Cash, 31-Dec-201582.6 K
Targeted Medical Pharma EV5.2 M

Targeted Medical Pharma Revenue

Targeted Medical Pharma revenue was $5.26 m in FY, 2015

Embed Graph

Targeted Medical Pharma Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015

Revenue

8.8m7.3m9.6m7.1m5.3m

Cost of goods sold

2.8m3.2m3.0m2.2m2.1m

Gross profit

6.1m4.1m6.6m4.9m3.2m

Gross profit Margin, %

69%56%69%69%60%

R&D expense

163.1k133.8k228.6k158.4k12.3k

General and administrative expense

11.7m10.1m10.2m7.3m5.2m

Operating expense total

11.8m10.2m10.4m7.5m5.2m

EBIT

(5.8m)(6.1m)(3.8m)(2.6m)(2.0m)

EBIT margin, %

(66%)(84%)(40%)(37%)(39%)

Interest expense

875.8k2.2m1.2m

Investment income

7.6k

Pre tax profit

(6.6m)(12.8m)(3.7m)(3.8m)(3.1m)

Income tax expense

(2.5m)(3.2m)5.7m65.8k

Net Income

(4.2m)(9.6m)(9.3m)(3.9m)(3.1m)

Targeted Medical Pharma Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015

Cash

147.4k326.6k491.8k11.7k82.6k

Accounts Receivable

899.5k354.0k268.8k203.3k328.0k

Prepaid Expenses

241.2k211.7k

Inventories

495.8k478.5k595.8k127.2k92.2k

Current Assets

2.9m2.6m2.6m534.0k833.0k

PP&E

411.8k340.1k235.6k107.2k54.3k

Total Assets

9.0m11.8m5.0m2.5m2.4m

Accounts Payable

5.0m7.0m1.5m1.5m1.9m

Short-term debt

5.0m4.1m3.6m4.6m

Current Liabilities

7.5m12.3m11.3m12.3m14.7m

Long-term debt

754.8k122.3k103.7k

Total Debt

5.0m4.8m3.7m4.7m

Total Liabilities

8.4m13.8m12.0m12.5m15.3m

Common Stock

22.0k23.0k25.7k26.8k27.7k

Preferred Stock

Additional Paid-in Capital

4.7m11.7m16.0m16.9m17.0m

Retained Earnings

(4.1m)(13.7m)(23.0m)(26.9m)(30.0m)

Total Equity

607.4k(2.0m)(7.0m)(10.0m)(12.9m)

Financial Leverage

14.8 x-5.9 x-0.7 x-0.3 x-0.2 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015

Cash

132.3k3.6k10.8k44.6k4.2k57.9k25.9k167.9k92.6k25.1k40.5k223.2k21.4k20.6k

Accounts Receivable

26.5m29.7m621.3k568.3k554.1k519.9k312.0k397.2k362.4k397.0k238.0k159.2k181.6k273.1k

Prepaid Expenses

175.6k239.1k453.7k676.6k357.6k341.9k

Inventories

361.5k328.8k848.0k1.1m854.2k694.5k703.9k603.8k478.6k383.6k278.5k85.5k124.9k123.7k

Current Assets

27.6m30.9m3.0m3.7m2.9m2.9m2.4m2.4m2.3m1.7m1.2m897.7k556.6k660.0k

PP&E

496.0k463.5k378.1k422.3k384.2k315.9k293.6k259.6k203.0k170.8k138.8k91.3k79.0k67.9k

Total Assets

33.5m36.5m9.6m11.2m11.1m12.2m5.1m4.9m4.6m3.8m3.2m2.8m2.4m2.4m

Accounts Payable

2.5m3.8m5.3m5.9m6.5m2.2m1.9m2.2m1.5m1.4m1.4m2.1m1.9m2.0m

Short-term debt

5.7m5.1m3.8m4.0m4.0m3.5m4.3m4.0m4.4m

Current Liabilities

11.6m14.3m6.1m11.8m12.2m12.7m12.5m14.0m11.7m11.8m11.5m13.3m13.2m14.0m

Long-term debt

750.0k376.3k396.4k561.9k741.2k258.0k

Total Debt

5.7m5.1m4.6m4.4m4.0m3.9m4.8m4.7m4.7m

Total Liabilities

14.3m16.7m9.5m12.7m13.5m14.2m12.7m12.1m11.8m11.9m14.4m14.5m14.8m

Common Stock

22.0k22.0k22.0k22.0k22.1k23.0k23.9k24.0k26.4k26.4k26.6k26.8k27.4k27.7k

Preferred Stock

Additional Paid-in Capital

3.3m3.6m5.5m6.4m6.6m12.0m14.1m14.4m16.4m16.5m16.7m16.9m17.0m17.0m

Retained Earnings

15.9m16.1m(5.5m)(7.9m)(9.1m)(14.0m)(21.8m)(23.5m)(24.0m)(24.4m)(25.4m)(28.6m)(29.1m)(29.4m)

Total Equity

19.2m19.8m72.1k(1.5m)(2.5m)(2.0m)(7.7m)(9.1m)(7.5m)(7.9m)(8.7m)(11.6m)(12.1m)(12.3m)

Financial Leverage

1.7 x1.8 x132.6 x-7.5 x-4.5 x-6.2 x-0.7 x-0.5 x-0.6 x-0.5 x-0.4 x-0.2 x-0.2 x-0.2 x

Targeted Medical Pharma Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015

Net Income

(4.2m)(9.6m)(9.3m)(3.9m)(3.0m)

Depreciation and Amortization

457.8k435.8k411.9k401.9k230.7k

Accounts Receivable

(444.0k)330.2k85.2k65.5k(124.7k)

Inventories

(130.5k)17.3k(117.3k)468.6k35.0k

Accounts Payable

3.4m2.0m(663.6k)(37.1k)403.7k

Cash From Operating Activities

(2.6m)(2.4m)(2.0m)780.3k(1.3m)

Purchases of PP&E

(82.3k)(115.5k)(38.0k)

Cash From Investing Activities

(267.9k)(294.9k)(121.4k)

Short-term Borrowings

(659.7k)(1.4m)(600.5k)

Long-term Borrowings

(246.7k)

Cash From Financing Activities

2.2m2.8m2.3m(1.3m)1.3m

Net Change in Cash

(648.5k)179.2k165.2k(480.1k)70.9k

Interest Paid

375.6k514.2k132.2k

Income Taxes Paid

103.6k

Targeted Medical Pharma Ratios

USDQ2, 2011

Financial Leverage

1.7 x